Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Women Infertility - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Women Infertility - Pipeline Review, H1 2015', provides an overview of the Women Infertility's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Women Infertility - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Women Infertility - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Women Infertility Overview 10 Therapeutics Development 11 Pipeline Products for Women Infertility - Overview 11 Pipeline Products for Women Infertility - Comparative Analysis 12 Women Infertility - Therapeutics under Development by Companies 13 Women Infertility - Therapeutics under Investigation by Universities/Institutes 18 Women Infertility - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Women Infertility - Products under Development by Companies 24 Women Infertility - Products under Investigation by Universities/Institutes 29 Women Infertility - Companies Involved in Therapeutics Development 30 AbbVie Inc. 30 Actavis plc 31 Addex Therapeutics Ltd 32 AlphaMab Co., Ltd 33 APAvadis Biotechnologies Srl 34 ASKA Pharmaceutical Co., Ltd. 35 Astellas Pharma Inc. 36 AstraZeneca PLC 37 Bayer AG 38 Crinetics Pharmaceuticals, Inc. 39 Dong-A Socio Group 40 Dongkook Pharmaceutical Co., Ltd. 41 EffRx Pharmaceuticals S.A. 42 ElexoPharm GmbH 43 EndoCeutics, Inc. 44 Euroscreen S.A. 45 Evotec AG 46 Ferring International Center S.A. 47 Finox AG 48 Forendo Pharma Oy 49 GlaxoSmithKline plc 50 Glycotope GmbH 51 Isifer AB 52 Kissei Pharmaceutical Co., Ltd. 53 Lipicard Technologies Limited 54 Merck & Co., Inc. 55 Merck KGaA 56 Neurocrine Biosciences, Inc. 57 Nora Therapeutics, Inc. 58 ObsEva SA 59 Orphagen Pharmaceuticals, Inc. 60 Pantec Biosolutions AG 61 PharmaEssentia Corporation 62 Philogen S.p.A. 63 PlasmaTech Biopharmaceuticals, Inc. 64 PregLem SA 65 Reliance Life Sciences Pvt. Ltd. 66 Repros Therapeutics Inc. 67 SK Chemicals Co., Ltd. 68 Takeda Pharmaceutical Company Limited 69 Teva Pharmaceutical Industries Limited 70 Trophogen, Inc. 71 ValiRx Plc 72 Zydus Cadila Healthcare Limited 73 Women Infertility - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Combination Products 75 Assessment by Target 76 Assessment by Mechanism of Action 79 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 (anastrozole + levonorgestrel) - Drug Profile 85 acolbifene hydrochloride + GnRH agonist + prasterone - Drug Profile 86 ADX-68692 - Drug Profile 87 AKP-501 - Drug Profile 88 ASP-1707 - Drug Profile 89 AZD-4901 - Drug Profile 90 barusiban - Drug Profile 91 BAY-1026153 - Drug Profile 92 BAY-1128688 - Drug Profile 93 bentamapimod - Drug Profile 94 Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 95 Biosimilar 5 for Infertility - Drug Profile 96 Biosimilar 6 for Infertility - Drug Profile 97 Biosimilar 7 for Infertility and Oncology - Drug Profile 98 choriogonadotropin alfa - Drug Profile 99 choriogonadotropin alfa biosimilar - Drug Profile 100 corifollitropin alfa - Drug Profile 101 DR-2011 - Drug Profile 103 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 104 Drug to Target RERG for Endometriosis - Drug Profile 105 Drugs for Endometriosis - Drug Profile 106 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 107 elagolix sodium - Drug Profile 108 Endole - Drug Profile 110 epelsiban besylate - Drug Profile 111 ESN-364 - Drug Profile 113 EVE-104 - Drug Profile 114 FE-999310 - Drug Profile 115 follitropin alfa - Drug Profile 116 follitropin alfa - Drug Profile 117 follitropin alfa (recombinant) - Drug Profile 118 follitropin delta - Drug Profile 120 FP-5677 - Drug Profile 121 FSH-GEX - Drug Profile 122 goserelin biosimilar - Drug Profile 124 Isifera - Drug Profile 125 kisspeptin - Drug Profile 126 KLH-2109 - Drug Profile 127 KN-015 - Drug Profile 128 LM-001 - Drug Profile 129 LM-002 - Drug Profile 130 LT-6121 - Drug Profile 131 menotropins - Drug Profile 132 metformin hydrochloride - Drug Profile 133 Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 134 NCE-403 - Drug Profile 135 NT-100 - Drug Profile 136 OBE-001 - Drug Profile 137 Oral Fertility Drugs - Drug Profile 138 PEG-FSH - Drug Profile 139 Peptides for Cancer and Endometriosis - Drug Profile 140 Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 141 PGL-1001 - Drug Profile 142 PGL-2001 - Drug Profile 143 PGL-3001 - Drug Profile 144 progesterone nanoparticles - Drug Profile 145 Progesterone Second Generation - Drug Profile 146 Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 147 Recombinant Protein to Agonize Luteinizing Hormone for Infertility - Drug Profile 148 relugolix - Drug Profile 149 RTPR-013 - Drug Profile 150 Small Molecule to Agonize FSHR for Infertility - Drug Profile 151 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 152 Small Molecules for Female Infertility - Drug Profile 153 Small Molecules to Antagonize GnRH for Endometriosis, Uterine Fibroids, PCOS and Oncology - Drug Profile 154 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 155 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 156 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 157 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 158 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 159 Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 160 Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 161 SR-16234 - Drug Profile 162 Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Drug Profile 163 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 164 telapristone acetate - Drug Profile 165 Tetravil - Drug Profile 168 TR-4401 - Drug Profile 170 triptorelin - Drug Profile 171 triptorelin pamoate biosimilar - Drug Profile 172 VAL-201 - Drug Profile 173 vilaprisan - Drug Profile 174 VPE-001 - Drug Profile 175 Women Infertility - Recent Pipeline Updates 176 Women Infertility - Dormant Projects 195 Women Infertility - Discontinued Products 199 Women Infertility - Product Development Milestones 201 Featured News & Press Releases 201 Appendix 207 Methodology 207 Coverage 207 Secondary Research 207 Primary Research 207 Expert Panel Validation 207 Contact Us 207 Disclaimer 208
List of Tables Number of Products under Development for Women Infertility, H1 2015 17 Number of Products under Development for Women Infertility - Comparative Analysis, H1 2015 18 Number of Products under Development by Companies, H1 2015 20 Number of Products under Development by Companies, H1 2015 (Contd..1) 21 Number of Products under Development by Companies, H1 2015 (Contd..2) 22 Number of Products under Development by Companies, H1 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2015 25 Comparative Analysis by Late Stage Development, H1 2015 26 Comparative Analysis by Clinical Stage Development, H1 2015 27 Comparative Analysis by Early Stage Development, H1 2015 28 Comparative Analysis by Unknown Stage Development, H1 2015 29 Products under Development by Companies, H1 2015 30 Products under Development by Companies, H1 2015 (Contd..1) 31 Products under Development by Companies, H1 2015 (Contd..2) 32 Products under Development by Companies, H1 2015 (Contd..3) 33 Products under Development by Companies, H1 2015 (Contd..4) 34 Products under Investigation by Universities/Institutes, H1 2015 35 Women Infertility - Pipeline by AbbVie Inc., H1 2015 36 Women Infertility - Pipeline by Actavis plc, H1 2015 37 Women Infertility - Pipeline by Addex Therapeutics Ltd, H1 2015 38 Women Infertility - Pipeline by AlphaMab Co., Ltd, H1 2015 39 Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H1 2015 40 Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 41 Women Infertility - Pipeline by Astellas Pharma Inc., H1 2015 42 Women Infertility - Pipeline by AstraZeneca PLC, H1 2015 43 Women Infertility - Pipeline by Bayer AG, H1 2015 44 Women Infertility - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 45 Women Infertility - Pipeline by Dong-A Socio Group, H1 2015 46 Women Infertility - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 47 Women Infertility - Pipeline by EffRx Pharmaceuticals S.A., H1 2015 48 Women Infertility - Pipeline by ElexoPharm GmbH, H1 2015 49 Women Infertility - Pipeline by EndoCeutics, Inc., H1 2015 50 Women Infertility - Pipeline by Euroscreen S.A., H1 2015 51 Women Infertility - Pipeline by Evotec AG, H1 2015 52 Women Infertility - Pipeline by Ferring International Center S.A., H1 2015 53 Women Infertility - Pipeline by Finox AG, H1 2015 54 Women Infertility - Pipeline by Forendo Pharma Oy, H1 2015 55 Women Infertility - Pipeline by GlaxoSmithKline plc, H1 2015 56 Women Infertility - Pipeline by Glycotope GmbH, H1 2015 57 Women Infertility - Pipeline by Isifer AB, H1 2015 58 Women Infertility - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 59 Women Infertility - Pipeline by Lipicard Technologies Limited, H1 2015 60 Women Infertility - Pipeline by Merck & Co., Inc., H1 2015 61 Women Infertility - Pipeline by Merck KGaA, H1 2015 62 Women Infertility - Pipeline by Neurocrine Biosciences, Inc., H1 2015 63 Women Infertility - Pipeline by Nora Therapeutics, Inc., H1 2015 64 Women Infertility - Pipeline by ObsEva SA, H1 2015 65 Women Infertility - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 66 Women Infertility - Pipeline by Pantec Biosolutions AG, H1 2015 67 Women Infertility - Pipeline by PharmaEssentia Corporation, H1 2015 68 Women Infertility - Pipeline by Philogen S.p.A., H1 2015 69 Women Infertility - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 70 Women Infertility - Pipeline by PregLem SA, H1 2015 71 Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 72 Women Infertility - Pipeline by Repros Therapeutics Inc., H1 2015 73 Women Infertility - Pipeline by SK Chemicals Co., Ltd., H1 2015 74 Women Infertility - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75 Women Infertility - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76 Women Infertility - Pipeline by Trophogen, Inc., H1 2015 77 Women Infertility - Pipeline by ValiRx Plc, H1 2015 78 Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 79 Assessment by Monotherapy Products, H1 2015 80 Assessment by Combination Products, H1 2015 81 Number of Products by Stage and Target, H1 2015 83 Number of Products by Stage and Mechanism of Action, H1 2015 86 Number of Products by Stage and Route of Administration, H1 2015 88 Number of Products by Stage and Molecule Type, H1 2015 90 Women Infertility Therapeutics - Recent Pipeline Updates, H1 2015 182 Women Infertility - Dormant Projects, H1 2015 201 Women Infertility - Dormant Projects (Contd..1), H1 2015 202 Women Infertility - Dormant Projects (Contd..2), H1 2015 203 Women Infertility - Dormant Projects (Contd..3), H1 2015 204 Women Infertility - Discontinued Products, H1 2015 205 Women Infertility - Discontinued Products (Contd..1), H1 2015 206
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
